Based on these data, WT1 is a useful marker of disease and of response to JAK2 inhibitors especially for patients without blasts and for patients who develop anemia or thrombocytopenia not for progression but as therapy‐related toxicity. This evidence concerns the gene WT1 and Thrombocytopenia.